Methicillin-resistant Staphylococcus aureus infection rate after implementation of an antibiotic care bundle based on results of rapid molecular screening
Colonization with methicillin-resistant Staphylococcus aureus (MRSA) is a risk factor for subsequent invasive MRSA infection, particularly in patients admitted to critical areas. We conducted a surveillance among patients admitted to our Intensive Care Unit (ICU) to determine whether the implementat...
Gespeichert in:
| Veröffentlicht in: | In vivo (Athens) 2013-11, Vol.27 (6), p.873-876 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 876 |
|---|---|
| container_issue | 6 |
| container_start_page | 873 |
| container_title | In vivo (Athens) |
| container_volume | 27 |
| creator | Stano, Paola Avolio, Manuela De Rosa, Rita Modolo, Maria Luisa Camporese, Alessandro |
| description | Colonization with methicillin-resistant Staphylococcus aureus (MRSA) is a risk factor for subsequent invasive MRSA infection, particularly in patients admitted to critical areas. We conducted a surveillance among patients admitted to our Intensive Care Unit (ICU) to determine whether the implementation of a specific MRSA antibiotic care bundle (ACB) based on rapid molecular screening for MRSA and de-colonization, reduced the total MRSA infection rate.
A total of 431 and 577 nasal swabs were obtained from ICU patients at admission from April 2009 through December 2010 (pre-ACB period) and, after the bundle implementation, from January 2011 through December 2012 (post-ACB period), respectively. Nasal swabs were analyzed by the rapid molecular test Xpert MRSA. All patients were followed-up during their whole ICU stay to determine whether they developed MRSA infection.
Overall, 31 out of 431 (7.1%) patients were colonized with MRSA at admission during the pre-ACB period and 49 out of 577 (8.4%) were colonized with MRSA during the post-ACB period. The rate of MRSA infection in ICU significantly declined from 2% in pre-ACB to 0.3% in post-ACB, with a total decrease of 100% in two consecutive semesters between July 2011 and July 2012 (p |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1464491653</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1464491653</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-d613923e478c1f0708747c6cb4b3ea34d37a20b1eb7abb7ef937f82130e926343</originalsourceid><addsrcrecordid>eNo1kMlOwzAURSMkREvhF5CXbCLFQ-J6iSomqYgFsI6enRdq5NjBw6K_wtfSMkhPOot77l28k2pJpaK1bIVaVOcpfTRNJ5uGnVULJphirWqX1dcT5p011jnr64jJpgw-k5cM827vggnGlESgRDzA-hFNtsGTCBkJjBkjsdPscEKf4ScJIwF_uGy1DdkaYiAi0cUP7gBIOJBjH1NxOR3tCLMdyBQcmuIgkmQiorf-_aI6HcElvPzjqnq7u33dPNTb5_vHzc22nhmluR46yhXjKOTa0LGRzVoKaTqjheYIXAxcAms0RS1Ba4mj4nJcM8obVKzjgq-q69_dOYbPgin3k00GnQOPoaSeik4IRbuWH9SrP7XoCYd-jnaCuO___8m_ASFedJ4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1464491653</pqid></control><display><type>article</type><title>Methicillin-resistant Staphylococcus aureus infection rate after implementation of an antibiotic care bundle based on results of rapid molecular screening</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Stano, Paola ; Avolio, Manuela ; De Rosa, Rita ; Modolo, Maria Luisa ; Camporese, Alessandro</creator><creatorcontrib>Stano, Paola ; Avolio, Manuela ; De Rosa, Rita ; Modolo, Maria Luisa ; Camporese, Alessandro</creatorcontrib><description>Colonization with methicillin-resistant Staphylococcus aureus (MRSA) is a risk factor for subsequent invasive MRSA infection, particularly in patients admitted to critical areas. We conducted a surveillance among patients admitted to our Intensive Care Unit (ICU) to determine whether the implementation of a specific MRSA antibiotic care bundle (ACB) based on rapid molecular screening for MRSA and de-colonization, reduced the total MRSA infection rate.
A total of 431 and 577 nasal swabs were obtained from ICU patients at admission from April 2009 through December 2010 (pre-ACB period) and, after the bundle implementation, from January 2011 through December 2012 (post-ACB period), respectively. Nasal swabs were analyzed by the rapid molecular test Xpert MRSA. All patients were followed-up during their whole ICU stay to determine whether they developed MRSA infection.
Overall, 31 out of 431 (7.1%) patients were colonized with MRSA at admission during the pre-ACB period and 49 out of 577 (8.4%) were colonized with MRSA during the post-ACB period. The rate of MRSA infection in ICU significantly declined from 2% in pre-ACB to 0.3% in post-ACB, with a total decrease of 100% in two consecutive semesters between July 2011 and July 2012 (p<0.001).
The analysis demonstrated a significant decline in MRSA infections following the introduction of active rapid molecular surveillance and the specific ACB at our ICU and in the risk associated with MRSA bacteremia.</description><identifier>EISSN: 1791-7549</identifier><identifier>PMID: 24292595</identifier><language>eng</language><publisher>Greece</publisher><subject>Anti-Bacterial Agents - administration & dosage ; Cross Infection - diagnosis ; Cross Infection - epidemiology ; Cross Infection - prevention & control ; Humans ; Intensive Care Units ; Methicillin-Resistant Staphylococcus aureus ; Molecular Diagnostic Techniques ; Nose - microbiology ; Patient Care Bundles ; Prevalence ; Risk ; Staphylococcal Infections - diagnosis ; Staphylococcal Infections - epidemiology ; Staphylococcal Infections - prevention & control ; Vancomycin - administration & dosage</subject><ispartof>In vivo (Athens), 2013-11, Vol.27 (6), p.873-876</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24292595$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stano, Paola</creatorcontrib><creatorcontrib>Avolio, Manuela</creatorcontrib><creatorcontrib>De Rosa, Rita</creatorcontrib><creatorcontrib>Modolo, Maria Luisa</creatorcontrib><creatorcontrib>Camporese, Alessandro</creatorcontrib><title>Methicillin-resistant Staphylococcus aureus infection rate after implementation of an antibiotic care bundle based on results of rapid molecular screening</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>Colonization with methicillin-resistant Staphylococcus aureus (MRSA) is a risk factor for subsequent invasive MRSA infection, particularly in patients admitted to critical areas. We conducted a surveillance among patients admitted to our Intensive Care Unit (ICU) to determine whether the implementation of a specific MRSA antibiotic care bundle (ACB) based on rapid molecular screening for MRSA and de-colonization, reduced the total MRSA infection rate.
A total of 431 and 577 nasal swabs were obtained from ICU patients at admission from April 2009 through December 2010 (pre-ACB period) and, after the bundle implementation, from January 2011 through December 2012 (post-ACB period), respectively. Nasal swabs were analyzed by the rapid molecular test Xpert MRSA. All patients were followed-up during their whole ICU stay to determine whether they developed MRSA infection.
Overall, 31 out of 431 (7.1%) patients were colonized with MRSA at admission during the pre-ACB period and 49 out of 577 (8.4%) were colonized with MRSA during the post-ACB period. The rate of MRSA infection in ICU significantly declined from 2% in pre-ACB to 0.3% in post-ACB, with a total decrease of 100% in two consecutive semesters between July 2011 and July 2012 (p<0.001).
The analysis demonstrated a significant decline in MRSA infections following the introduction of active rapid molecular surveillance and the specific ACB at our ICU and in the risk associated with MRSA bacteremia.</description><subject>Anti-Bacterial Agents - administration & dosage</subject><subject>Cross Infection - diagnosis</subject><subject>Cross Infection - epidemiology</subject><subject>Cross Infection - prevention & control</subject><subject>Humans</subject><subject>Intensive Care Units</subject><subject>Methicillin-Resistant Staphylococcus aureus</subject><subject>Molecular Diagnostic Techniques</subject><subject>Nose - microbiology</subject><subject>Patient Care Bundles</subject><subject>Prevalence</subject><subject>Risk</subject><subject>Staphylococcal Infections - diagnosis</subject><subject>Staphylococcal Infections - epidemiology</subject><subject>Staphylococcal Infections - prevention & control</subject><subject>Vancomycin - administration & dosage</subject><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMlOwzAURSMkREvhF5CXbCLFQ-J6iSomqYgFsI6enRdq5NjBw6K_wtfSMkhPOot77l28k2pJpaK1bIVaVOcpfTRNJ5uGnVULJphirWqX1dcT5p011jnr64jJpgw-k5cM827vggnGlESgRDzA-hFNtsGTCBkJjBkjsdPscEKf4ScJIwF_uGy1DdkaYiAi0cUP7gBIOJBjH1NxOR3tCLMdyBQcmuIgkmQiorf-_aI6HcElvPzjqnq7u33dPNTb5_vHzc22nhmluR46yhXjKOTa0LGRzVoKaTqjheYIXAxcAms0RS1Ba4mj4nJcM8obVKzjgq-q69_dOYbPgin3k00GnQOPoaSeik4IRbuWH9SrP7XoCYd-jnaCuO___8m_ASFedJ4</recordid><startdate>20131101</startdate><enddate>20131101</enddate><creator>Stano, Paola</creator><creator>Avolio, Manuela</creator><creator>De Rosa, Rita</creator><creator>Modolo, Maria Luisa</creator><creator>Camporese, Alessandro</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20131101</creationdate><title>Methicillin-resistant Staphylococcus aureus infection rate after implementation of an antibiotic care bundle based on results of rapid molecular screening</title><author>Stano, Paola ; Avolio, Manuela ; De Rosa, Rita ; Modolo, Maria Luisa ; Camporese, Alessandro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-d613923e478c1f0708747c6cb4b3ea34d37a20b1eb7abb7ef937f82130e926343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Anti-Bacterial Agents - administration & dosage</topic><topic>Cross Infection - diagnosis</topic><topic>Cross Infection - epidemiology</topic><topic>Cross Infection - prevention & control</topic><topic>Humans</topic><topic>Intensive Care Units</topic><topic>Methicillin-Resistant Staphylococcus aureus</topic><topic>Molecular Diagnostic Techniques</topic><topic>Nose - microbiology</topic><topic>Patient Care Bundles</topic><topic>Prevalence</topic><topic>Risk</topic><topic>Staphylococcal Infections - diagnosis</topic><topic>Staphylococcal Infections - epidemiology</topic><topic>Staphylococcal Infections - prevention & control</topic><topic>Vancomycin - administration & dosage</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stano, Paola</creatorcontrib><creatorcontrib>Avolio, Manuela</creatorcontrib><creatorcontrib>De Rosa, Rita</creatorcontrib><creatorcontrib>Modolo, Maria Luisa</creatorcontrib><creatorcontrib>Camporese, Alessandro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stano, Paola</au><au>Avolio, Manuela</au><au>De Rosa, Rita</au><au>Modolo, Maria Luisa</au><au>Camporese, Alessandro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Methicillin-resistant Staphylococcus aureus infection rate after implementation of an antibiotic care bundle based on results of rapid molecular screening</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2013-11-01</date><risdate>2013</risdate><volume>27</volume><issue>6</issue><spage>873</spage><epage>876</epage><pages>873-876</pages><eissn>1791-7549</eissn><abstract>Colonization with methicillin-resistant Staphylococcus aureus (MRSA) is a risk factor for subsequent invasive MRSA infection, particularly in patients admitted to critical areas. We conducted a surveillance among patients admitted to our Intensive Care Unit (ICU) to determine whether the implementation of a specific MRSA antibiotic care bundle (ACB) based on rapid molecular screening for MRSA and de-colonization, reduced the total MRSA infection rate.
A total of 431 and 577 nasal swabs were obtained from ICU patients at admission from April 2009 through December 2010 (pre-ACB period) and, after the bundle implementation, from January 2011 through December 2012 (post-ACB period), respectively. Nasal swabs were analyzed by the rapid molecular test Xpert MRSA. All patients were followed-up during their whole ICU stay to determine whether they developed MRSA infection.
Overall, 31 out of 431 (7.1%) patients were colonized with MRSA at admission during the pre-ACB period and 49 out of 577 (8.4%) were colonized with MRSA during the post-ACB period. The rate of MRSA infection in ICU significantly declined from 2% in pre-ACB to 0.3% in post-ACB, with a total decrease of 100% in two consecutive semesters between July 2011 and July 2012 (p<0.001).
The analysis demonstrated a significant decline in MRSA infections following the introduction of active rapid molecular surveillance and the specific ACB at our ICU and in the risk associated with MRSA bacteremia.</abstract><cop>Greece</cop><pmid>24292595</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7549 |
| ispartof | In vivo (Athens), 2013-11, Vol.27 (6), p.873-876 |
| issn | 1791-7549 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1464491653 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Anti-Bacterial Agents - administration & dosage Cross Infection - diagnosis Cross Infection - epidemiology Cross Infection - prevention & control Humans Intensive Care Units Methicillin-Resistant Staphylococcus aureus Molecular Diagnostic Techniques Nose - microbiology Patient Care Bundles Prevalence Risk Staphylococcal Infections - diagnosis Staphylococcal Infections - epidemiology Staphylococcal Infections - prevention & control Vancomycin - administration & dosage |
| title | Methicillin-resistant Staphylococcus aureus infection rate after implementation of an antibiotic care bundle based on results of rapid molecular screening |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T03%3A02%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Methicillin-resistant%20Staphylococcus%20aureus%20infection%20rate%20after%20implementation%20of%20an%20antibiotic%20care%20bundle%20based%20on%20results%20of%20rapid%20molecular%20screening&rft.jtitle=In%20vivo%20(Athens)&rft.au=Stano,%20Paola&rft.date=2013-11-01&rft.volume=27&rft.issue=6&rft.spage=873&rft.epage=876&rft.pages=873-876&rft.eissn=1791-7549&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1464491653%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1464491653&rft_id=info:pmid/24292595&rfr_iscdi=true |